STADA Arzneimittel AG
Industry Group: Pharmaceuticals
STADA Arzneimittel AG is a specialty and generic drug manufacturing company. The vast majority of the company's sales are derived from its generic drug products, followed by its branded products. It operates in three segments: Generics, Consumer Healthcare, and Specialty. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
ESG Risk Rating
Industry Group (1st = lowest risk)
Pharmaceuticals 102 out of 901
Global Universe 5315 out of 15361
What are the ESG Risk Ratings?
Notice: The information provided is for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. Usage as a credit rating or as a benchmark is not permitted. Unless otherwise explicitly agreed in writing, usage for products and services, index creation, derivative work, portfolio or fund management, or any other usage are not permitted. By way of exception, usage is permitted only to the rated company, limited to a single reference of its own information in annual reporting and sustainability website, mentioning Sustainalytics as a source.
|Company||ESG Risk Rating||Industry Rank|
|Grünenthal Pharma GmbH & Co. KG||
|96 out of 901|
|STADA Arzneimittel AG||
|102 out of 901|
|144 out of 901|
|491 out of 901|
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
STADA Arzneimittel AG's Exposure is Medium
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
STADA Arzneimittel AG's Management of ESG Material Risk is Strong
How do the ESG Risk Ratings work?
Top Material ESG Issues for STADA Arzneimittel AG
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Highest Controversy level that has impacted STADA Arzneimittel AG's ESG Risk Rating in the last three years
Highest Controversy Level